BRCA2 and breast cancer: The following year, Tulinius et al. [46] examined the effect of a single Icelandic founder BRCA2 PV (999del5) on cancer risk among families of 995 breast cancer patients in Iceland, 90 of whom tested positive for the BRCA2 founder.